NCT01706666 · OUTCOME

Survival Time

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant · Source last updated 2018-09-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Months to death
Interval / dispersion: Not reported
Time frame: From registration to death due to any cause, assessed up to 3 years

What was measured

The distribution of survival time will be estimated by arm using the method of Kaplan-Meier.

Analysis population: All patients are still alive

Groups in this outcome

Arm A

Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.

Arm B

Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.

Arm C

Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm A	1
Arm B	1
Arm C	1

Reported measurements

Source class 1

Values in Months to death · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm A	NA	Not reported	Not reported	Not reported	No Deaths
Arm B	NA	Not reported	Not reported	Not reported	No Deaths
Arm C	NA	Not reported	Not reported	Not reported	No Deaths

Complete source fields

classes

categories
measurements
comment
No Deaths
group Id
OG000
value
NA
comment
No Deaths
group Id
OG001
value
NA
comment
No Deaths
group Id
OG002
value
NA

denoms

counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
units
Participants

description

The distribution of survival time will be estimated by arm using the method of Kaplan-Meier.

groups

description
Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
id
OG000
title
Arm A
description
Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
id
OG001
title
Arm B
description
Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.
id
OG002
title
Arm C

param Type

NUMBER

population Description

All patients are still alive

reporting Status

POSTED

time Frame

From registration to death due to any cause, assessed up to 3 years

title

Survival Time

type

SECONDARY

unit Of Measure

Months to death

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice